Recent Advances in Acute Promyelocytic Leukaemia

Overview

Journal F1000Res

Specialties Biomedical Engineering
Science

Date 2017 Aug 11

PMID 28794865

Citations 7

Authors

Chin-Hin Ng

Wee-Joo Chng

Affiliations

Soon will be listed here.

Abstract

Acute promyelocytic leukaemia (APML) is a subtype of leukaemia arising from a distinct reciprocal translocation involving chromosomes 15 and 17, which results in the fusion gene. Over the past three decades, APML has been transformed from a highly fatal disease to a highly curable one. This drastic improvement is because of the introduction of a new treatment strategy with all-trans retinoic acid and, more recently, arsenic trioxide. The revolutionary treatment of APML has also paved the way for a new cancer treatment, which is genetically targeted therapy. In this review, we look into this amazing journey of transformation and provide recent advances in the management of APML.

Citing Articles

Coagulation Abnormalities and Risk Assessment in Acute Promyelocytic Leukemia: An Experience From a Resource-Constraint Country.

Thakur W, Anwar N, Fatima N, Jamal A, Rizvi Q, Borhany M Cureus. 2022; 14(6):e26026.

PMID: 35865439 PMC: 9293264. DOI: 10.7759/cureus.26026.

Transcriptomic profiling of blood from autoimmune hepatitis patients reveals potential mechanisms with implications for management.

Tana M, Klepper A, Lyden A, Pisco A, Phelps M, McGee B PLoS One. 2022; 17(3):e0264307.

PMID: 35312680 PMC: 8936448. DOI: 10.1371/journal.pone.0264307.

G/M cell cycle arrest and apoptosis induced by COH-203 in human promyelocytic leukemia HL-60 cells.

Lin J, Zhang L, Wang Z, Guan Q, Bao K, Wu L Oncol Lett. 2021; 22(6):815.

PMID: 34671429 PMC: 8503807. DOI: 10.3892/ol.2021.13076.

AXL receptor tyrosine kinase: a possible therapeutic target in acute promyelocytic leukemia.

Fatima M, Kakar S, Adnan F, Khan K, Mian A, Khan D BMC Cancer. 2021; 21(1):713.

PMID: 34140003 PMC: 8210361. DOI: 10.1186/s12885-021-08450-y.

Ubiquitin and SUMO conjugation as biomarkers of acute myeloid leukemias response to chemotherapies.

Gatel P, Brockly F, Reynes C, Pastore M, Hicheri Y, Cartron G Life Sci Alliance. 2020; 3(6).

PMID: 32303586 PMC: 7167290. DOI: 10.26508/lsa.201900577.

References

Fenaux P, Le Deley M, Castaigne S, Archimbaud E, Chomienne C, Link H . Effect of all transretinoic acid in newly diagnosed acute promyelocytic leukemia. Results of a multicenter randomized trial. European APL 91 Group. Blood. 1993; 82(11):3241-9. View

Shinagawa K, Yanada M, Sakura T, Ueda Y, Sawa M, Miyatake J . Tamibarotene as maintenance therapy for acute promyelocytic leukemia: results from a randomized controlled trial. J Clin Oncol. 2014; 32(33):3729-35. DOI: 10.1200/JCO.2013.53.3570. View

Redner R, Rush E, Faas S, Rudert W, Corey S . The t(5;17) variant of acute promyelocytic leukemia expresses a nucleophosmin-retinoic acid receptor fusion. Blood. 1996; 87(3):882-6. View

Au W, Tam S, Fong B, Kwong Y . Determinants of cerebrospinal fluid arsenic concentration in patients with acute promyelocytic leukemia on oral arsenic trioxide therapy. Blood. 2008; 112(9):3587-90. DOI: 10.1182/blood-2008-06-161000. View

Madan V, Shyamsunder P, Han L, Mayakonda A, Nagata Y, Sundaresan J . Comprehensive mutational analysis of primary and relapse acute promyelocytic leukemia. Leukemia. 2016; 30(12):2430. PMC: 7609306. DOI: 10.1038/leu.2016.237. View

Evans G, Grimwade D . Extramedullary disease in acute promyelocytic leukemia. Leuk Lymphoma. 1999; 33(3-4):219-29. DOI: 10.3109/10428199909058422. View

Marchetti M, Falanga A, Giovanelli S, Oldani E, Barbui T . All-trans-retinoic acid increases adhesion to endothelium of the human promyelocytic leukaemia cell line NB4. Br J Haematol. 1996; 93(2):360-6. DOI: 10.1046/j.1365-2141.1996.4911029.x. View

Beitinjaneh A, Jang S, Roukoz H, Majhail N . Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations in acute promyelocytic leukemia: a systematic review. Leuk Res. 2010; 34(7):831-6. DOI: 10.1016/j.leukres.2010.01.001. View

Jin B, Hou K, Liu Y, Yu P . Leukocytosis and retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. Chin Med Sci J. 2006; 21(3):171-4. View

10.

Camacho L, Soignet S, Chanel S, Ho R, Heller G, Scheinberg D . Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide. J Clin Oncol. 2000; 18(13):2620-5. DOI: 10.1200/JCO.2000.18.13.2620. View

11.

Niu C, Yan H, Yu T, Sun H, Liu J, Li X . Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients. Blood. 1999; 94(10):3315-24. View

12.

Abaza Y, Kantarjian H, Garcia-Manero G, Estey E, Borthakur G, Jabbour E . Long-term outcome of acute promyelocytic leukemia treated with all--retinoic acid, arsenic trioxide, and gemtuzumab. Blood. 2016; 129(10):1275-1283. PMC: 5413297. DOI: 10.1182/blood-2016-09-736686. View

13.

Tallman M, Andersen J, Schiffer C, Appelbaum F, Feusner J, Woods W . All-trans retinoic acid in acute promyelocytic leukemia: long-term outcome and prognostic factor analysis from the North American Intergroup protocol. Blood. 2002; 100(13):4298-302. DOI: 10.1182/blood-2002-02-0632. View

14.

Sanz M, Montesinos P, Vellenga E, Rayon C, de la Serna J, Parody R . Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline monochemotherapy: long-term outcome of the LPA 99 multicenter study by the PETHEMA Group. Blood. 2008; 112(8):3130-4. DOI: 10.1182/blood-2008-05-159632. View

15.

Lo-Coco F, Avvisati G, Vignetti M, Thiede C, Orlando S, Iacobelli S . Retinoic acid and arsenic trioxide for acute promyelocytic leukemia. N Engl J Med. 2013; 369(2):111-21. DOI: 10.1056/NEJMoa1300874. View

16.

Yoo E . Recent advances in the diagnosis and management of childhood acute promyelocytic leukemia. Korean J Pediatr. 2011; 54(3):95-105. PMC: 3121002. DOI: 10.3345/kjp.2011.54.3.95. View

17.

Creutzig U, Dworzak M, Bochennek K, Faber J, Flotho C, Graf N . First experience of the AML-Berlin-Frankfurt-Münster group in pediatric patients with standard-risk acute promyelocytic leukemia treated with arsenic trioxide and all-trans retinoid acid. Pediatr Blood Cancer. 2017; 64(8). DOI: 10.1002/pbc.26461. View

18.

Rashidi A, Silverberg M, Conkling P, Fisher S . Thrombosis in acute promyelocytic leukemia. Thromb Res. 2012; 131(4):281-9. DOI: 10.1016/j.thromres.2012.11.024. View

19.

Zhang Y, Zhang Z, Li J, Li L, Han X, Han L . Long-term efficacy and safety of arsenic trioxide for first-line treatment of elderly patients with newly diagnosed acute promyelocytic leukemia. Cancer. 2012; 119(1):115-25. DOI: 10.1002/cncr.27650. View

20.

Shen Z, Shi Z, Fang J, Gu B, Li J, Zhu Y . All-trans retinoic acid/As2O3 combination yields a high quality remission and survival in newly diagnosed acute promyelocytic leukemia. Proc Natl Acad Sci U S A. 2004; 101(15):5328-35. PMC: 397380. DOI: 10.1073/pnas.0400053101. View